Immatics N.V. (IMTX)
| Market Cap | 513.77M |
| Revenue (ttm) | 172.83M |
| Net Income (ttm) | 37.51M |
| Shares Out | 76.23M |
| EPS (ttm) | 0.55 |
| PE Ratio | 12.25 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 669,132 |
| Open | 7.09 |
| Previous Close | 6.74 |
| Day's Range | 6.17 - 7.09 |
| 52-Week Range | 5.75 - 13.60 |
| Beta | 0.51 |
| Analysts | Buy |
| Price Target | 20.06 (+197.63%) |
| Earnings Date | Mar 21, 2023 |
About IMTX
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients wi... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for IMTX stock is "Buy." The 12-month stock price forecast is $20.06, which is an increase of 197.63% from the latest price.
News
Immatics Announces Full Year 2022 Financial Results and Corporate Update
Tuebingen , Germany and Houston, TX , March 2 1 , 20 2 3 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redire...
Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates
Immatics (IMTX) delivered earnings and revenue surprises of -3.23% and 13.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Immatics Announces Third Quarter 2022 Financial Results and Business Update
Tuebingen , Germany and Houston, Texas , November 1 7 , 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-re...
Does Immatics (IMTX) Have the Potential to Rally 77% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 76.9% in Immatics (IMTX). While the effectiveness of this highly sought-after metric is questionable, the posit...
Wall Street Analysts See an 81% Upside in Immatics (IMTX): Can the Stock Really Move This High?
The mean of analysts' price targets for Immatics (IMTX) points to an 81.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys...
Immatics (IMTX) Moves 11.6% Higher: Will This Strength Last?
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Is Immatics (IMTX) Stock Up 7% Today?
Source: CI Photos / Shutterstock.com Immatics (NASDAQ: IMTX) stock is climbing higher on Monday after the clinical-stage biopharmaceutical company revealed details of an underwritten public offering....
Immatics Announces $110 Million Underwritten Offering of Ordinary Shares
H ouston, Texas and Tuebingen , Germany , October 10, 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redi...
Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME
Company to host conf e rence call today, October 10 , at 8:30 am E D T / 2:30 pm CEST
Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
TCER® IMA402 is a next-generation, half-life extended TCR Bispecific targeting an HLA-A*02:01-presented peptide derived from PRAME. In preclinical studies, IMA402 demonstrated enhanced anti-tumor acti...
Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME
H ouston, Texas and Tuebingen , Germany , August 23 , 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redi...
Wall Street Analysts Think Immatics (IMTX) Could Surge 82%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 81.5% in Immatics (IMTX). While the effectiveness of this highly sought-after metric is questionable, the posit...
Immatics (IMTX) Reports Q2 Loss, Lags Revenue Estimates
Immatics (IMTX) delivered earnings and revenue surprises of -276.92% and 56.96%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Immatics Announces Second Quarter 2022 Financial Results and Business Update
Tuebingen , Germany and Houston, Texas , August 9 , 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redire...
Strength Seen in Immatics (IMTX): Can Its 18% Jump Turn into More Strength?
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Immatics (IMTX) Stock Jumps 5.2%: Will It Continue to Soar?
Immatics (IMTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength d...
Why you should consider buying and accumulating Immatics N.V.
Immatics N.V. (NASDAQ:IMTX) is currently valued at $7.55.
BMY, IMTX Extend Deal to Develop Cell Therapies for Cancer
Bristol Myers (BMY) strengthens its partnership with the small biotech company Immatics (IMTX) to develop multiple allogenic cell therapies targeting multiple cancer indications.
Immatics (IMTX) Lags Q1 Earnings and Revenue Estimates
Immatics (IMTX) delivered earnings and revenue surprises of -18.28% and 23.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Bristol Myers Squibb, Immatics expand CAR-T agreement
Shares of Immatics IMTX, +3.85% gained 9.0% in premarket trading on Thursday after the company said its deal with Bristol Myers Squibb Inc. BMY, -0.65% has expanded to include several off-the-shelf TC...
Immatics Announces First Quarter 2022 Financial Results and Business Update
Tuebingen, Germany and Houston, Texas , June 2 , 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti...
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
TUEBINGEN, Germany & HOUSTON & NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of ...
Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors
H ouston, Texas and Tuebingen , Germany , May XX , 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirec...
Strength Seen in Immatics (IMTX): Can Its 5.3% Jump Turn into More Strength?
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors
Tuebingen , Germany and Houston, Texas , May 10 , 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirect...